🧬 ICD-10 CM C32.9 — Malignant Neoplasm of Larynx, Unspecified
Billable Code Confirmed
ICD-10 CM C32.9 is a complete, billable 4-character ICD-10-CM code effective for FY2026 (10/01/2025-09/30/2026). Unlike many neoplasm sites, the larynx is a single midline structure, so this category never requires a laterality character or 7th-character extension — once you have a valid subsite (or confirm none is documented), the code is final.1
Non-Billable Parent Code
C32 (Malignant neoplasm of larynx) is the 3-character category header and cannot be billed on its own — it exists only to organize the six 4-character children below it, and AAPC/icd10data both flag it explicitly as not for reimbursement use.1,3 There is no intermediate non-billable layer between C32 and its children for this category, which is unusual; most neoplasm categories have at least one further subdivision step.
Clinical Context
“Unspecified” here means the pathology, operative, or imaging documentation does not identify which laryngeal subsite — glottis, supraglottis, subglottis, or laryngeal cartilage — harbors the tumor, not that the diagnosis itself is uncertain. The distinction matters because glottic and supraglottic cancers behave very differently (glottic tumors are often diagnosed early due to hoarseness; supraglottic tumors present later and spread to neck nodes more readily), so C32.9 should be a true last resort after the chart has been reviewed for subsite language, not a default landing spot.
Code Classification
This is a diagnosis code (ICD-10-CM), not a procedure code. The corresponding procedure — laryngoscopy with biopsy, partial laryngectomy, or total laryngectomy — is reported separately via CPT (profee) or ICD-10-PCS (facility inpatient), both referenced below.
🔍 Code Description
Malignant neoplasm of the larynx refers to primary or, less commonly, metastatic malignant disease arising in the voice box — the cartilaginous structure that sits between the C32.1-coded supraglottis above and the C32.2-coded subglottis below, with the glottis (vocal cords themselves) as the most frequently affected and earliest-detected subsite. The overwhelming majority of cases are squamous cell carcinoma, strongly associated with tobacco and heavy alcohol use, which is why the C32 category carries a category-level “use additional code” instruction for tobacco dependence (F17.-), tobacco use (Z72.0), and alcohol abuse/dependence (F10.-) rather than an excludes note.1,3 Other histologies (verrucous carcinoma, chondrosarcoma of the laryngeal framework) exist but are uncommon enough that documentation should be reviewed carefully before assuming squamous histology.
ICD-10 CM C32.9 is assigned specifically when the medical record establishes a malignant laryngeal tumor but does not document which of the named subsites is involved — for example, a pathology report confirming squamous cell carcinoma from a laryngeal biopsy without an operative or imaging report specifying glottic versus supraglottic origin. This differs meaningfully from C32.8, which is used when the documentation does specify the tumor spans two or more subsites (a “transglottic” tumor crossing the glottis and supraglottis, for instance) — C32.8 reflects positive multi-site documentation, while C32.9 reflects the absence of subsite documentation entirely. Coders working profee charts should treat C32.9 as a CDI query trigger whenever the operative note, laryngoscopy report, or radiology read contains enough anatomic detail to support a more specific code, since unspecified-site malignancy codes are a known target for both quality-of-data audits and payer-side specificity reviews.
🌳 Code Tree / Hierarchy
C32 Malignant neoplasm of larynx ❌ Non-billable
│
├── C32.0 Malignant neoplasm of glottis ✅ Billable
├── C32.1 Malignant neoplasm of supraglottis ✅ Billable
├── C32.2 Malignant neoplasm of subglottis ✅ Billable
├── C32.3 Malignant neoplasm of laryngeal cartilage ✅ Billable
├── C32.8 Malignant neoplasm of overlapping sites of larynx ✅ Billable
└── C32.9 Malignant neoplasm of larynx, unspecified ◀ THIS CODE ✅ Billable
Flat Hierarchy, No Laterality
All six C32 children are billable at 4 characters with no further subdivision and no laterality character — this is one of the simplest neoplasm hierarchies in the chapter, so there’s no risk of a “looks complete but isn’t” code here the way there is with paired-organ neoplasms (kidney, breast, lung).
Tip
Selection between siblings is driven entirely by what the pathology and operative documentation say about tumor location, never by stage, size, or treatment plan. A T4 tumor with subsite documented still gets the specific code; a T1 tumor without subsite documented still gets C32.9.
✅ Includes
- Malignant tumors of the larynx where the operative, pathology, or imaging report does not name a specific subsite (glottis, supraglottis, subglottis, laryngeal cartilage).
- Squamous cell carcinoma of the larynx, site not otherwise specified — the most common histology captured under this code.
- Laryngeal carcinoma described only as “cancer of the larynx” or “laryngeal malignancy” in clinician shorthand without anatomic qualifier.
- Both newly diagnosed primary tumors and recurrent/persistent disease at an unspecified laryngeal site, as long as the disease remains active (not resolved — see Z85.21 for history).
❌ Excludes
Excludes 1
No formal Excludes1 note exists under C32 or C32.9 in the ICD-10-CM tabular — the category carries only the “use additional code” instruction for tobacco/alcohol comorbidity, not a mutual-exclusivity note.1 The closest functional equivalent is the specificity hierarchy within C32 itself: C32.0, C32.1, and C32.8 each represent a more documented alternative to C32.9 for the same tumor, and only one code from the category should ever be assigned per primary lesion.
Danger
The most common error here isn’t an official Excludes1 violation — it’s coders defaulting to C32.9 when the operative or pathology report actually does name a subsite, simply because the H&P or discharge summary used generic language like “laryngeal cancer.” Always trace back to the source documentation (path report, OR note, scope findings) before finalizing as unspecified.
Excludes 2
Info
ICD-10 CM C77.0 (Secondary malignant neoplasm of lymph nodes of head, face, and neck) is reportable in addition to C32.9 when pathology confirms regional nodal metastasis from the laryngeal primary — sequence C32.9 first as the primary site, C77.0 second.1 Z85.21 (Personal history of malignant neoplasm of larynx) can also be reported alongside C32.9 in the narrow scenario of a genuinely separate, previously resolved laryngeal malignancy coexisting with a new, distinct active primary — it should never be substituted for C32.9 to describe ongoing surveillance of the same still-active tumor.
📋 Clinical Overview
Unspecified vs. Glottic vs. Supraglottic — Why Subsite Drives Everything
The three most clinically distinct laryngeal cancer presentations are glottic, supraglottic, and the unspecified default, and the table below frames why a CDI query for subsite is almost always worth the effort. Glottic tumors involve the vocal cords directly and have a sparse lymphatic supply, which means they present early (hoarseness) and metastasize late. Supraglottic tumors arise above the cords in a region rich with lymphatics, so they tend to present later with a neck mass or dysphagia and carry a meaningfully higher rate of nodal spread at diagnosis. C32.9 sits clinically “blind” between these two patterns since the subsite — and therefore the expected behavior — is unknown.
| Feature | C32.9 | C32.0 (Glottis) | C32.1 (Supraglottis) |
|---|---|---|---|
| Typical presentation | Variable/unknown — depends entirely on undocumented tumor location | Early hoarseness, voice change; often caught at low stage | Dysphagia, referred ear pain, or palpable neck mass; often caught at higher stage |
| Lymphatic spread risk | Cannot be assessed without subsite — assume highest-risk pattern until clarified | Low (sparse lymphatics) — nodal involvement is a late finding | High (rich lymphatic plexus) — nodal involvement common even at presentation |
| Typical surgical approach | Cannot be planned definitively; biopsy/staging precedes any subsite-specific procedure | Cordectomy, vertical partial laryngectomy, or transoral laser microsurgery for early disease | Supraglottic (horizontal) partial laryngectomy or total laryngectomy depending on extent |
CDI Trigger
Manifestations & Symptom Burden
- Hoarseness or voice change — the hallmark early symptom, especially with glottic involvement.
- Dysphagia or odynophagia — more typical with supraglottic or advanced disease.
- Referred otalgia (ear pain) without ear pathology — a classic supraglottic/hypopharyngeal referred-pain pattern.
- Palpable neck mass — often the presenting sign when nodal metastasis (codeable separately as C77.0) is the first clinical clue.
- Stridor or airway compromise in advanced disease, occasionally requiring emergent tracheostomy ahead of definitive resection.
Tip
💰 HCC Risk Adjustment
| Model | HCC | Category Name | Notes |
|---|---|---|---|
| CMS-HCC V24 | HCC 11 | Colorectal, Bladder, and Other Cancers | Legacy model, largely phased out by 2026 |
| CMS-HCC V28 | HCC 21 | Lymphoma and Other Cancers | Fully phased in for payment year 20264,5 |
The V24-to-V28 transition split the old, broader cancer HCCs into more granular categories, and laryngeal cancer landed in a different bucket as a result — this is exactly the kind of mapping shift that can change a patient’s RAF score without any change in their actual clinical status, so don’t be surprised if year-over-year RAF comparisons for the same ENT oncology patient look different purely due to model version. Active malignancy HCCs require annual recapture; if treatment concludes and surveillance shows no evidence of disease, the correct move is to transition documentation toward Z85.21 rather than continuing to report C32.9 indefinitely, since “history of” codes don’t carry the same RAF weight and continuing to report active disease after resolution is a RADV exposure in itself.
🏥 MS-DRG Assignment
| Path | DRG | Title | Trigger |
|---|---|---|---|
| Default (MDC 03) | 146/147/148 | Ear, Nose, Mouth and Throat Malignancy w/MCC, w/CC, w/o CC-MCC | C32.9 as principal diagnosis, no laryngectomy/tracheostomy performed |
| Pre-MDC override | 011/012/013 | Tracheostomy for Face, Mouth and Neck Diagnoses or Laryngectomy w/MCC, w/CC, w/o CC-MCC | Laryngectomy (total or partial) or tracheostomy performed during the same stay2,6 |
ICD-10 CM C32.9 itself is not a CC or MCC, so a 148 vs. 147 vs. 146 split for the default path depends entirely on other secondary diagnoses on the claim (acute respiratory failure, aspiration pneumonia, postprocedural hemorrhage, malnutrition, etc.), not on the cancer diagnosis itself.6 The pre-MDC tracheostomy/laryngectomy DRGs carry meaningfully higher relative weights than the MDC 03 malignancy DRGs, so missing the override on a chart where a laryngectomy was performed is a direct underpayment risk — this is the single highest-value DRG check on any inpatient laryngeal cancer surgical case.
🔗 Related ICD-10 CM Codes
Sibling Subsite Codes (C32 category): C32.0, C32.1, C32.2, C32.3, C32.8
Related Head & Neck / Sequela Codes: C77.0, Z85.21, J38.00, R49.0
🛠️ Commonly Associated CPT Codes
- 31575 (Laryngoscopy, flexible; diagnostic) — typically the first-line scope used to visualize the tumor and obtain staging information before any biopsy or resection is planned.
- 31535 (Laryngoscopy, direct, operative, with biopsy) — the procedure that actually yields the pathology confirming malignancy; this is usually the encounter that establishes the C32.9 diagnosis in the first place.
- 31360 (Laryngectomy; total, without radical neck dissection) — definitive surgical treatment when neck disease is absent or addressed separately.
- 31367 (Laryngectomy; subtotal supraglottic, without radical neck dissection) — voice-sparing option for appropriately staged supraglottic disease.
- 31390 (Pharyngolaryngectomy with radical neck dissection; without reconstruction) — bundled code for advanced disease requiring both laryngeal and pharyngeal resection plus nodal clearance in one session.
- 38720 (Cervical lymphadenectomy, complete) — reported separately only when neck dissection is performed as a distinct procedure and isn’t already bundled into the laryngectomy code selected.
NCCI Bundling Considerations
A diagnostic scope (31575) performed immediately before a same-session therapeutic procedure on the same lesion is bundled into the definitive code and isn’t separately billable; the diagnostic component is presumed inherent to surgical planning. Biopsy codes (31535/31536) follow the same logic when the biopsy precedes definitive resection in the same operative session — only the higher-value resection code is reported. Codes that already incorporate radical neck dissection in their descriptor (31365, 31390) should never be paired with a stand-alone neck dissection code (38720-38724) for the same anatomic field; doing so is an unbundling pattern that profee auditors flag routinely on head and neck oncology claims.
🔬 ICD-10-PCS Crosswalk
- 0CTS0ZZ — Resection of Larynx, Open Approach. Facility-side code for total laryngectomy performed via traditional open neck incision, the most common approach for this procedure.
- 0CTS7ZZ — Resection of Larynx, Via Natural or Artificial Opening. Used when total laryngectomy is approached through an existing tracheostomy or natural orifice rather than a fresh open incision — confirmed valid in the official PCS table.7
- 0CBS0ZZ — Excision of Larynx, Open Approach. Root operation Excision (not Resection) applies for partial/subtotal laryngectomy, since only part of the body part is being taken.
- 0CBS8ZX — Excision of Larynx, Via Natural or Artificial Opening Endoscopic, Diagnostic. The facility-side PCS equivalent of a direct laryngoscopy with biopsy — note the qualifier “Diagnostic” (X), which is what differentiates a biopsy from a therapeutic partial resection at the PCS level.7
💊 Coding Scenarios and Examples
Scenario 1 — Subsite Not Documented at Admission. A 64-year-old smoker is admitted for elective direct laryngoscopy with biopsy after months of progressive hoarseness; the operative note describes “a friable laryngeal mass” without specifying glottic vs. supraglottic origin, and pathology returns squamous cell carcinoma. Correct coding: C32.9 as principal diagnosis, 31535 for the profee biopsy procedure. Sequencing places the malignancy first since it’s both the reason for admission and the definitive pathologic finding. CDI note: flag for a query if the discharge summary later references a more specific location based on imaging, since the inpatient record may be updated before final coding.
Scenario 2 — Total Laryngectomy with Neck Dissection. A patient with biopsy-proven C32.9 disease and a palpable neck mass undergoes total laryngectomy with radical neck dissection in the same operative session; final pathology confirms nodal metastasis. Correct coding: C32.9 as principal diagnosis, C77.0 as secondary diagnosis for the confirmed nodal spread, with 31365 (total laryngectomy with radical neck dissection) on the profee side and 0CTS0ZZ on the facility PCS side. Sequencing: the primary malignancy leads, the secondary nodal disease follows. This case also triggers the pre-MDC DRG override (011/012/013) on the facility side due to the laryngectomy procedure.
Scenario 3 — Post-Treatment Aspiration Pneumonia. A patient with a history of laryngeal cancer treated to no evidence of disease six months ago is admitted with aspiration pneumonia related to chronic dysphagia from prior partial laryngectomy. Correct coding: aspiration pneumonia (J69.0) as principal diagnosis, Z85.21 as a secondary diagnosis to capture the cancer history, and NOT C32.9, since the malignancy itself is resolved. CDI note: confirm with the attending that there’s no evidence of recurrent or persistent disease before finalizing Z85.21 over an active code — this is the exact distinction the Excludes 2 relationship between C32.9 and Z85.21 is meant to protect.
⚠️ Coding Pitfalls and Tips
- Defaulting to C32.9 without tracing the path report. The discharge summary often uses generic language (“laryngeal cancer”) even when the operative or pathology report names a specific subsite. Always verify against the primary source document before finalizing as unspecified — this is the single highest-frequency specificity error on these charts.
- Confusing primary laryngeal mucosal cancer with skin cancer of the neck. Squamous cell carcinoma of the laryngeal mucosa (C32.9) is a completely different code family from skin cancer overlying the neck — this exact confusion shows up repeatedly in AAPC coding forums and is worth flagging proactively in any CDI education.
- Forgetting the tobacco/alcohol “use additional code” instruction. The C32 category instructs coders to also report tobacco dependence/use (F17.-/Z72.0) and alcohol abuse/dependence (F10.-) when documented — skipping this both undercodes the case for quality reporting purposes and misses an HCC capture opportunity in its own right.
- Missing the pre-MDC DRG override. Any laryngectomy or tracheostomy performed during the stay should pull the case out of MDC 03 (DRGs 146-148) and into pre-MDC (DRGs 011-013) — confirm the PCS code is captured and correctly sequenced before finalizing the DRG.
- Using Z85.21 and C32.9 interchangeably. Z85.21 is for resolved disease only; using it to describe ongoing surveillance of an active tumor (or, conversely, continuing to report C32.9 after treatment has concluded with no evidence of disease) is a documentation-accuracy error that affects both HCC capture and registry data quality.
- Assuming C32.9 carries CC/MCC weight. It doesn’t — the malignancy diagnosis itself has zero CC/MCC influence, so DRG severity for the default (non-laryngectomy) path is determined entirely by other secondary diagnoses on the claim.